Drugs and Driving Research in Medicinal Drug Development

J. G. Ramaekers

doi:10.1016/j.tips.2017.01.006

Drugs and Driving Research in Medicinal Drug Development

J. G. Ramaekers^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Medicinal drugs that cause drowsiness and inattentiveness may impair driving. The FDA recently emphasized that standardized procedures for measuring drug effects on driving are needed as part of drug registration. Here, I provide an overview of a standardized on-the-road driving test that offers maximal drug sensitivity and uses a real-life outcome measure of driver impairment that is strongly associated with crash risk.

Original language	English
Pages (from-to)	319-321
Number of pages	3
Journal	Trends in Pharmacological Sciences
Volume	38
Issue number	4
DOIs	https://doi.org/10.1016/j.tips.2017.01.006
Publication status	Published - Apr 2017

Access to Document

10.1016/j.tips.2017.01.006

Cite this

@article{55aee14dffe5446fabf442b826e52c2c,

title = "Drugs and Driving Research in Medicinal Drug Development",

abstract = "Medicinal drugs that cause drowsiness and inattentiveness may impair driving. The FDA recently emphasized that standardized procedures for measuring drug effects on driving are needed as part of drug registration. Here, I provide an overview of a standardized on-the-road driving test that offers maximal drug sensitivity and uses a real-life outcome measure of driver impairment that is strongly associated with crash risk.",

author = "Ramaekers, \{J. G.\}",

year = "2017",

month = apr,

doi = "10.1016/j.tips.2017.01.006",

language = "English",

volume = "38",

pages = "319--321",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

publisher = "Elsevier Ltd",

number = "4",

}

TY - JOUR

T1 - Drugs and Driving Research in Medicinal Drug Development

AU - Ramaekers, J. G.

PY - 2017/4

Y1 - 2017/4

N2 - Medicinal drugs that cause drowsiness and inattentiveness may impair driving. The FDA recently emphasized that standardized procedures for measuring drug effects on driving are needed as part of drug registration. Here, I provide an overview of a standardized on-the-road driving test that offers maximal drug sensitivity and uses a real-life outcome measure of driver impairment that is strongly associated with crash risk.

AB - Medicinal drugs that cause drowsiness and inattentiveness may impair driving. The FDA recently emphasized that standardized procedures for measuring drug effects on driving are needed as part of drug registration. Here, I provide an overview of a standardized on-the-road driving test that offers maximal drug sensitivity and uses a real-life outcome measure of driver impairment that is strongly associated with crash risk.

U2 - 10.1016/j.tips.2017.01.006

DO - 10.1016/j.tips.2017.01.006

M3 - Article

C2 - 28283199

SN - 0165-6147

VL - 38

SP - 319

EP - 321

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

IS - 4

ER -

Drugs and Driving Research in Medicinal Drug Development

Abstract

Access to Document

Fingerprint

Cite this